Zhenwei Miao

This inventor holds 50 USPTO granted patents and 13 published patent applications, plus 7 CIPO patents and 17 EPO patents, primarily in Drug-Conjugates. Top assignees: Ambrx, Inc., Enanta Pharmaceuticals, Inc., Concortis Biosystems, Corp.. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhenwei Miao. Retrieved from https://idiyas.com/inventor/zhenwei-miao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 50 (Patent Applications = 13)

% Patents Active = 68.0

CIPO Patents = 7 (Patent Applications = 4)

EPO Patents = 17 (Patent Applications = 15)

Average Co-Inventor Count = 4.4

ph-index = 17

Forward Citations = 699(Granted Patents)

Location History:

Medway, MA (US) (2006 - 2010)
San Diego, CA (US) (2007 - 2024)

Company Filing History:

Enanta Pharmaceuticals, Inc.

patents

4 out of 4

Concortis Biosystems, Corp.

patents

4. 2 out of 114

Sorrento Therapeutics, Inc.

Concortis Biosystems, Corp., a Wholly Owned Subsidiary of Sorrento Therapeutics, Inc.

patent

8. 1 out of 26

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

10. 1 out of 834,513

Other

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Drug-Conjugates

Antibody-Drug Conjugates

Non-Natural Amino Acids

Polypeptides

Conjugation Methods

Hepatitis C Inhibitors

Dolastatin Derivatives

Modified Insulin Polypeptides

Targeting Molecules

Preparation Methods

Composition Uses

Accelerants

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622944 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2026-05-12),

2. 12115228 - Drug-conjugates, conjugation methods, and uses thereof (2024-10-15),

3. 11987622 - Drug-conjugates with a targeting molecule and two different drugs (2024-05-21),

4. 11903948 - Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof (2024-02-20),

5. 11420999 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2022-08-23),

6. 10967071 - Drug-conjugates, conjugation methods, and uses thereof (2021-04-06),

7. 10954270 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2021-03-23),

8. 10836821 - Drug-conjugates with a targeting molecule and two different drugs (2020-11-17),

9. 10590165 - Antibody drug conjugates (2020-03-17),

10. 9981046 - Drug-conjugates, conjugation methods, and uses thereof (2018-05-29),

11. 9884127 - Drug-conjugates, conjugation methods, and uses thereof (2018-02-06),

12. 9801951 - Drug-conjugates, conjugation methods, and uses thereof (2017-10-31),

13. 9796754 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2017-10-24),

14. 9637441 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides (2017-05-02),

15. 9586988 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides (2017-03-07),

Hello! How can I assist you today?

Profile summary based on public USPTO records.